Trialbee Helps AstraZeneca Reduce the Time Required for Recruitment of Patients to Clinical Trials

STOCKHOLM--()--AstraZeneca: (STO:AZN)(LSE:AZN)

E-health company Trialbee signs professional service agreement with AstraZeneca for e-recruitment. Trialbee enables AstraZeneca to recruit patients into specific clinical trials faster and more effectively reducing the clinical trial time.

The professional service agreement with AstraZeneca is strategically important for Trialbee. AstraZeneca can use Trialbee´s services for e-recruitment globally, covering multiple therapeutic areas and study phases.

“We are very happy to announce the agreement with AstraZeneca. For Trialbee, it’s a significant opportunity to work closely with a Big Pharma company providing our solutions efficiently over multiple regions and domains. AstraZeneca is one of the top 10 Big Pharma companies in the world and a leader in research and development with a very attractive pipeline. Trialbee can support patient recruitment across AstraZeneca’s portfolio with potential to realize significant efficiency gains. With the agreement in place we can start working on a long term basis finding the best solutions for AstraZeneca.” Jonas Billing, VP Sales Trialbee.

“Trialbee’s direct-to-patient approach is very attractive since it enables patients to easily engage in clinical trials. This follows the trend of patients increasingly searching for disease and treatment information online. Trialbee’s solution helps patients to explore and access information about ongoing research and connects the stakeholders conducting clinical trials. Trialbee’s solution has the potential to be used in many of our therapeutic areas and on many local markets going forward”. Jenny Skogsberg, Clinical Development Manager, AstraZeneca.

“The service agreement with AstraZeneca is an important milestone in Trialbee’s establishment on the arena for global pharmaceutical companies. We are delighted to cooperate with AstraZeneca, a company in the forefront of R&D that engages patients in the product development”. Tobias Folkesson, CEO Trialbee.

About AstraZeneca:

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

About Trialbee:

Trialbee is a software company specialized in clinical trial planning and management solutions. Trialbee provides global pharmaceutical companies a web-based solution for accurate and effective patient recruitment to clinical trials. The technical platform has been developed in close collaboration with pharmaceutical and CRO companies. Trialbee was founded in Lund in 2010 by Tobias Folkesson and Jonas Billing and has 12 employees today. For further information please visit our website www.trialbee.com

This information was brought to you by Cision http://news.cision.com

Contacts

Trialbee
Tobias Folkesson, CEO
+46 70 582 11 01
tobias.folkesson@trialbee.com

Contacts

Trialbee
Tobias Folkesson, CEO
+46 70 582 11 01
tobias.folkesson@trialbee.com